Impaired
Sanofi’s E. coli Vaccine Fails Phase 3 Trial, Resulting in $250M Impairment Charge
Sanofi, Johnson & Johnson, E. coli vaccine, Phase 3 failure, impairment charge, clinical trial discontinuation
AstraZeneca Discontinues Vemircopan, Takes $753M Charge on Former Alexion Asset
AstraZeneca, Alexion, vemircopan, complement inhibitor, drug discontinuation, impairment charge, rare diseases, pharmaceutical industry